Coronavirus (COVID-19) information for Dana-Farber patients & familiesLearn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request alive medical interpreter for a discussion about your care.
Menu
For Patients & Families
Ursula Matulonis博士(Ursula Matulonis, MD)
预约
转载须知
阁下若有媒体联络需求,敬请致电617-632-4090,请阁下指明与媒体团队洽谈;或请发邮件至media@dfci.harvard.edu。阁下如欲转载本文,请发邮件至kun_ma@dfci.harvard.edu,未经授权禁止转载,感谢合作。
免疫疗法(immunotherapy)已经为若干种癌症的治愈带来了新的希望。现在,研究人员试图将他们从早期临床试验中获得的知识,应用到为复发性宫颈癌(recurrent cervical cancer)患者提供更多的治疗方案上。
尽管宫颈癌疫苗和癌症筛查为预防和诊断宫颈癌提供了重大突破,但宫颈癌仍是在妇女死亡率中排名第二的癌症。
“宫颈癌是一个巨大的世界性问题,而且还没有得到足够的重视,”丹娜-法伯的苏珊∙F∙史密斯女性癌症中心(Susan F. Smith Center for Women’s Cancers)妇科肿瘤学主任医师Ursula Matulonis (Ursula Matulonis, MD)说。